Exploring the Significance of Pharmaceutical Care in Mental Health: A Spotlight on Cannabis

Author:

da Costa-Oliveira Claudete12,Pereira Michele Lafayette3ORCID,de Carvalho Nicole Ferrari4,Silvério Luiza Aparecida Luna4ORCID,Jessé Ramos Ygor5ORCID,Mazzola Priscila Gava4ORCID

Affiliation:

1. Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas 13083-887, Brazil

2. APEPI—Medicinal Cannabis Research and Patient Support Association, Rio de Janeiro 20040-030, Brazil

3. Faculdade de Ciências Biológicas e Saúde, Universidade do Estado do Rio de Janeiro, Campus Zona Oeste, Rio de Janeiro 23070-200, Brazil

4. Faculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas, Campinas 13083-871, Brazil

5. Farmácia da Terra Laboratory, Faculty of Pharmacy, Federal University of Bahia, Salvador 40170-115, Brazil

Abstract

Although preliminary evidence suggests Cannabis’s efficacy in symptom control for anxiety and depression—psychiatric disorders that significantly impact mental health—much remains to be understood about its effects on the central nervous system (CNS) and how to optimize treatment for these disorders. This study aims to conduct a narrative review to evaluate pharmaceutical care in treating symptoms of anxiety and depression alongside Cannabis use, focusing on safety and therapeutic efficacy optimization. We seek to conceptualize anxiety and depression disorders, review evidence on Cannabis use, evaluate the evidence quality, and identify knowledge gaps. Twelve articles were identified, revealing a significant gap in the literature regarding the integration of pharmaceutical care with Cannabis-based therapies, specifically for anxiety and depression. Despite a growing interest in the relationship between Cannabis and mental health, current research is insufficient for a comprehensive understanding. The relationship between Cannabis use and anxiety and depression disorders requires further, more targeted investigations. This study underscores the importance of future research to fill existing gaps, providing informed insights and robust guidelines for the safe and effective use of Cannabis as part of the treatment for anxiety and depression. It is crucial that pharmaceutical care integrates these therapies responsibly to improve the overall well-being of patients.

Funder

CNPq

FAPESP

Publisher

MDPI AG

Reference81 articles.

1. World Health Organization (2022). Fact Sheets of Mental Disorders, World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/mental-disorders.

2. Government of the Netherlands (2024, February 15). Mental Health and Psychosocial Support in Crisis Situations: MHPSS Worldwide: Facts and Figures, Available online: https://www.government.nl/topics/mhpss/mhpss-worldwide-facts-and-figures#:~:text=According%20to%20the%20WEF%2C%20poor,in%20MHPSS%20has%20economic%20benefits.

3. World Health Organization (2022). World Mental Health Report: Transforming Mental Health for All, World Health Organization.

4. Huang, F., and Wu, X. (2021). Brain neurotransmitter modulation by gut microbiota in anxiety and depression. Front. Cell Dev. Biol., 9.

5. Is depression a somatic disease or a psychiatric disorder?;Takeda;Cogn. Rehabil.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3